Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
64 hedge funds and large institutions have $84M invested in Mirati Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
49% more capital invested
Capital invested by funds: $56.5M → $84M (+$27.6M)
3% more funds holding
Funds holding: 62 → 64 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
59% less call options, than puts
Call options by funds: $48K | Put options by funds: $116K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$6.93M |
| 2 |
AH
Aviva Holdings
New Providence,
Bahamas
|
+$4.88M |
| 3 |
BlackRock
New York
|
+$4.83M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$4.8M |
| 5 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$3.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.13M |
| 2 |
RI
RTW Investments
New York
|
-$616K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$383K |
| 4 |
Millennium Management
New York
|
-$239K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$169K |
MRTX Hedge Fund Activity: Q1 2017 in Review
64 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2017, worth a combined $84M — up 49% from $56.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MRTX positions and 7 closed out — a net gain of 6 holders — while 26 added to existing stakes and 14 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $6.93M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.13M sold.
- 64 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2017, up from 62 in Q4 2016.
- Funds reported $84M of Mirati Therapeutics, Inc. Common Stock stock for Q1 2017, up 49% quarter-over-quarter.
- 13 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2017 and 7 closed out, a net change of +6 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2017 was Broadfin Capital, an estimated $6.93M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2017 was Great Point Partners, an estimated $4.13M sold.
Based on aggregated 13F filings for Q1 2017.